Artificial intelligence for aging and longevity research: Recent advances and perspectives

  title={Artificial intelligence for aging and longevity research: Recent advances and perspectives},
  author={Alex Zhavoronkov and Polina Mamoshina and Quentin Vanhaelen and Morten Scheibye-Knudsen and Alexey A. Moskalev and Alexander Aliper},
  journal={Ageing Research Reviews},

Figures from this paper

Transforming Drug Discovery for Aging Research with AI-Based Integrated Approaches

Advanced multimodal deep learning methods are transforming aging research and drug discovery and AI based platforms can be deployed to identify promising targets for aging-related diseases and AI can be used for the generation of novel drug-like compounds with good activity profiles and suitable chemical properties.

Artificial Intelligence Based Approaches to Identify Molecular Determinants of Exceptional Health and Life Span-An Interdisciplinary Workshop at the National Institute on Aging

The workshop involved experts in the fields of aging, comparative biology, cardiology, cancer, and computational science/AI who brainstormed ideas on how AI can be leveraged for the analyses of large-scale data sets from human epidemiological studies and animal/model organisms to close the current knowledge gaps in processes that drive exceptional life and health span.

Deep Integrated Biomarkers of Aging

This chapter provides a brief overview of the DACs, their advantages, and disadvantages as well as the commentary on the challenges in this emerging field.

AI in Longevity Medicine

These deep aging clocks (DACs) are being used by the research physicians to evaluate the effectiveness of longevity interventions, clinical trial enrollment and monitoring, risk profiling, biological target identification, and personalized medicine.

Deep learning for biological age estimation

This study identifies four broad classes of measures to quantify the performance of algorithms for biological age estimation and based on these evaluate the current approaches, which could have implications in different health care settings, from palliative care to public health.

Multi-Layer Picture of Neurodegenerative Diseases: Lessons from the Use of Big Data through Artificial Intelligence

This review will describe how relevant studies have been able to demonstrate the potential of deep learning to enhance the knowledge of neurodegenerative disorders such as Alzheimer's and Parkinson’s diseases through the integration of all sources of biomedical data.

Hallmarks of aging-based dual-purpose disease and age-associated targets predicted using PandaOmics AI-powered discovery engine

A variety of target identification and prioritization techniques offered by the AI-powered PandaOmics platform are used, to propose a list of promising novel aging-associated targets that may be used for drug discovery and reveal both high confidence and novel targets associated with multiple hallmarks of aging.

Integrated Multi-Omics for Novel Aging Biomarkers and Antiaging Targets

This review provides new insights regarding the discovery of aging biomarkers, mechanism of aging, and identification of novel antiaging targets and data from genomics, transcriptomics, proteomics, metabolomics, integromics, microbiomics, and systems biology contribute to the identification of new candidate biomarkers for aging and novel targets for antiaging interventions.



Deep biomarkers of human aging: Application of deep neural networks to biomarker development

The ensemble approach may facilitate integration of multi-modal data linked to chronological age and sex that may lead to simple, minimally invasive, and affordable methods of tracking integrated biomarkers of aging in humans and performing cross-species feature importance analysis.

Epigenetics of Aging and Longevity

Recent applications of deep learning and machine intelligence on in silico drug discovery: methods, tools and databases

The objective of this study is to examine and discuss the recent applications of machine learning techniques in VS, including deep learning, which became highly popular after giving rise to epochal developments in the fields of computer vision and natural language processing.

Opportunities and obstacles for deep learning in biology and medicine

This work examines applications of deep learning to a variety of biomedical problems -- patient classification, fundamental biological processes, and treatment of patients -- to predict whether deep learning will transform these tasks or if the biomedical sphere poses unique challenges.

Machine Learning on Human Muscle Transcriptomic Data for Biomarker Discovery and Tissue-Specific Drug Target Identification

This study confirms the established mechanisms of human skeletal muscle aging, including dysregulation of cytosolic Ca2+ homeostasis, PPAR signaling and neurotransmitter recycling along with IGFR and PI3K-Akt-mTOR signaling.

Extracting biological age from biomedical data via deep learning: too much of a good thing?

This work used one-week long physical activity records from a 2003–2006 National Health and Nutrition Examination Survey to compare three increasingly accurate biological age models and introduced a novel way to train parametric proportional hazards models suitable for out-of-the-box implementation with any modern machine learning software.

Applications of Deep Learning in Biomedicine.

Key features of deep learning that may give this approach an edge over other machine learning methods are discussed and a number of applications ofdeep learning in biomedical studies demonstrating proof of concept and practical utility are reviewed.

An epigenetic biomarker of aging for lifespan and healthspan

A new epigenetic biomarker of aging, DNAm PhenoAge, is developed that strongly outperforms previous measures in regards to predictions for a variety of aging outcomes, including all-cause mortality, cancers, healthspan, physical functioning, and Alzheimer’s disease.

Reinforced Adversarial Neural Computer for de Novo Molecular Design

An original deep neural network (DNN) architecture named RANC (Reinforced Adversarial Neural Computer) for the de novo design of novel small-molecule organic structures based on the generative adversarial network (GAN) paradigm and reinforcement learning (RL).

druGAN: An Advanced Generative Adversarial Autoencoder Model for de Novo Generation of New Molecules with Desired Molecular Properties in Silico.

This work developed an advanced AAE model for molecular feature extraction problems, and demonstrated its advantages compared to VAE in terms of adjustability in generating molecular fingerprints; capacity of processing very large molecular data sets; and efficiency in unsupervised pretraining for regression model.